Europe’s €30B Biologics Patent Cliff: The Complete Biosimilar Strategy Guide for Generic Manufacturers, IP Teams, and Investors
1. Executive Summary Between now and 2032, an estimated 110 biological medicines in Europe will lose intellectual property protection, with […]
